A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Folinic acid; Folinic acid; Mercaptopurine; Methotrexate; Pegaspargase; Pegaspargase; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Biomarker; Therapeutic Use
- 29 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Mar 2026.
- 29 May 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Mar 2026.
- 04 Apr 2024 Status changed from active, no longer recruiting to recruiting.